Heparin Market size is valued at $10.86Bn by 2019, and is anticipated to grow at a CAGR of 7.19% during the forecast period 2020-2025. The Heparin Market growth rate is attributed to the increasing incidences of coagulation disorders, substantial growth in the number of the people suffering from diseases like venous thromboembolism and heart diseases. is used to prevent formation of blood clots caused by certain medical conditions or medical procedures. It is used in the treatment for various health conditions such as acute coronary syndrome, deep-vein thrombosis, pulmonary embolism, atrial fibrillation, and is also used during heart surgery for carrying out cardiopulmonary bypass as well as hemofiltration. From increasing incidence of venous thromboembolism and cardiovascular disorders Increasing incidence of venous thromboembolism and cardiovascular disorders to increase in government funding toward improving healthcare facilities and extensive research and development (R&D) activities to develop heparin with improved therapeutic potential and minimal side-effects is anticipated to propel the Heparin Market during the forecast period 2020-2025.
The report: “Heparin Market Forecast (2020-2025)”, by Industry ARC, covers an in-depth analysis of the following segments of the Heparin Market:
By Source Type: Mammalian Sources and Non-Mammalian Sources.
By Product Type: High Molecular Weight Heparin, Unfractionated Heparin, Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin(ULMWH).
By Mode of Administration: Parenteral Administration and Oral Administration.
By Ingredients: Heparin Calcium, Heparin Sodium.
By Applications: Acute Coronary Syndrome, Anticoagulation During Pregnancy, Angina, Antiphospholipid Syndrome, Deep Vein Thrombosis, Deep Vein Thrombosis Prophylaxis, Heart Attack, Patency Maintenance of Indwelling Intravenous Devices, Pulmonary Embolism, Thrombotic/Thromboembolic Disorder, Venous Thromboembolism.
By Geography: North America, Europe, Asia-Pacific and RoW.
- North America dominated the Heparin Market with a share of 39% in the year 2019.
- The factors such as increase in mortality and prevalence of chronic diseases like cardiovascular disorders as heparin acts as an anticoagulant that prevents the formation of blood clots, it is used before surgery to reduce the risk of in the veins, arteries, or lungs are amongst the major factor projected to impel growth of Heparin Market.
- Improving healthcare infrastructure, higher healthcare expenditure levels, high patient awareness are the key factors owing to the growth in the segment during forecast period 2020-2025.
Route of Administration - Segment Analysis
Parenteral Administration segment held the largest share in the market owing to less cost associated with hospitalization. Also this method is preferred over oral mode owing to ease of administration, rising preference for home care and reduced duration of treatment. Moreover, the associated benefits of this route of administration includes low risk of systemic infection and improved quality of life.
Application Type- Segment Analysis
On the basis of Application type, deep vein thrombosis segment held the major share of the market in terms of revenue and is poised to grow with a CAGR of 7.1%. The reason is set to be attributed to the increasing awareness of thrombosis such as pulmonary embolism (PE) and deep vein thrombosis (DVT). Increasing prevalence and incidence of heart-related disorders is anticipated to further expand the consumption rate over the projection period of 2020-2025.
By Geography - Segment Analysis
North America dominated the Heparin Market with a share of 39% in 2019. North America remains the largest market owing to the growing awareness among consumers, constant improving healthcare infrastructure, presence of untapped opportunities, economic development, and rising initiatives by private and public organizations continues to expand its market. According to a report published in the American Heart Association, in 2018, around 92.1 million American adults were suffering from some form of cardiovascular disease. In addition, around 1 in every 3 deaths are caused by cardiovascular disease in the U.S. accounting for around 2,300 deaths per day. High initial capital investment on infrastructure, government funding toward improving healthcare facilities and extensive research and development (R&D) activities to develop heparin with improved therapeutic potential are to cater the Heparin Market in the forecast period of 2020-2025.
Drivers – Heparin Market
- Increasing Introduction of Biosimilar LMWH Anticoagulants Globally
With the increase in the introduction of various biosimilar LMWH Anticoagulants owing to increasing use in a number of Western European countries and emerging economies and its potential indications, such as thromboprophylaxis, Venous thromboembolism (VTE), anticoagulation treatment during pregnancy, among others. Enoxaparin is the bestselling LMWH worldwide. Therefore, pharmaceutical companies in many countries are focused on producing generic forms of LMWH which is to act as a key driver of the market during the forecast period 2020-2025.
Challenges – Heparin Market
- High initial capital and maintenance cost
The major challenge for the market is the high initial capital investment on infrastructure and the requirement of an improved healthcare facility for treatment and compliance in a vast and heterogeneous market. The stringent rules and regulations regarding the processing and preservation prior to distribution and sales is the major problem for some of the regions in Asia-Pacific.
UHT Processing Industry Outlook
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Heparin Market. In 2019, Heparin Market share is fragmented by the top ten players present in the market. Heparin Market top 10 companies are LEO Pharma A/S, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., Novartis AG, Sanofi, Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V., Aspen Holdings, changzhaou Qianhong Bio-pharma Co., ltd., Eisai Co., Ltd., Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, and others.
- In March, 2019 Bioiberica's Business Unit participated in DCAT 2019 with the objective of establishing strategic alliances and find new business opportunities by the help of these conferences in the US market.
1 Heparin Market Overview
1.1 Definitions and Scope
2. Heparin Market - Executive Summary
2.1 Market Revenue and Key Trends by Company
2.2 Key trends by Product Type
2.3 Key trends by Geography
3. Heparin Market – Comparative Analysis
3.1 Product Benchmarking – Key Companies
3.2 Financial Analysis – Key Companies
3.3 Market Value Split by Key Companies
3.4 Patent Analysis – Key Companies
3.5 Pricing Analysis
4. Heparin Market - Startup Companies Scenario (Premium)
4.1 Key Startup Company Analysis by
4.1.3 Venture Capital and Funding Scenario
5. Heparin Market – Industry Market Entry Scenario Premium (Premium)
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case Studies of Successful Ventures
6. Heparin Market Forces
6.1 Market Drivers
6.2 Market Constraints/Challenges
6.3 Porters five force model
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7. Heparin Market – Strategic Analysis
7.1 Value Chain Analysis
7.2 Opportunities Analysis
7.3 Market Life Cycle
8. Heparin Market – By Source Type
8.1 Mammalian Sources
8.2 Non-mammalian Sources
9. Heparin Market – By Product Type
9.1 High Molecular Weight Heparins
9.2 Unfractionated Heparin
9.3 Low Molecular Weight Heparin (LMWH)
9.4 Ultra-Low Molecular Weight Heparin (ULMWH)
10. Heparin Market – By Mode of Administration
10.1 Parenteral Administration
10.1.1 Intravenous Infusion
10.1.2 Subcutaneous Injection
11. Heparin Market – By Ingredients
11.1 Heparin Calcium
11.2 Heparin Sodium
12. Heparin Market – By Applications
12.1 Acute Coronary Syndrome
12.3 Anticoagulation During Pregnancy
12.4 Antiphospholipid Syndrome
12.5 Deep Vein Thrombosis
12.6 Deep Vein Thrombosis Prophylaxis
12.7 Deep Vein Thrombosis Prophylaxis
12.7.1 Abdominal Surgery
12.7.2 Hip Replacement Surgery
12.7.3 Knee Replacement Surgery
12.7.4 Orthopedic Surgery
12.8 Heart Attack
12.9 Patency Maintenance of Indwelling Intravenous Devices
12.10 Pulmonary Embolism
12.11 Thrombotic/Thromboembolic Disorder
12.12 Venous Thromboembolism
13. Heparin Market - By Geography
13.1 North America
13.2.6 Rest of Europe
13.3.4 South Korea
13.3.5 Australia & New Zealand
13.3.6 Rest of Asia-Pacific
13.4 Rest of the World
13.4.1 Middle East
13.4.3 South America
14. Heparin Market - Entropy
15. Heparin Market – Industry/Segment Competition Landscape (Premium)
15.1 Market Share Analysis
15.1.1 Global Market Share – Key Companies
15.1.2 Market Share by Region – Key companies
15.1.3 Market Share by Countries – Key Companies
15.1.4 Best Practices for Companies
16. Heparin Market – Key Company List by Country Premium (Premium)
17. Heparin Market Company Analysis
17.1 Company 1
17.2 Company 2
17.3 Company 3
17.4 Company 4
17.5 Company 5
17.6 Company 6
17.7 Company 7
17.8 Company 8
17.9 Company 9
17.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.